Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$2.45
+0.2%
$1.99
$1.11
$5.00
$650.71M1.811.76 million shs233,986 shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.71
+0.9%
$1.77
$0.99
$7.69
$86.51M2.71.60 million shs164,057 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$1.30
-1.9%
$1.62
$1.09
$7.67
$15.93M0.5348,143 shs19,033 shs
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$4.35
$1.10
$43.35
$2.55M1.83103,866 shs137,800 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-2.01%-1.21%+19.02%+70.63%-45.90%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
+3.68%-1.17%-12.66%+53.64%-78.50%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
+1.54%-6.38%-0.75%-34.65%-79.25%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
2.6382 of 5 stars
3.51.00.00.02.63.30.6
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
2.9328 of 5 stars
3.54.00.00.03.10.80.6
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
4.249 of 5 stars
3.53.00.04.33.81.70.0
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32281.19% Upside
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43746.25% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.00208.88% Upside
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CASI, EIGR, AUTL, and CABA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/12/2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/19/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
$10.12M64.30N/AN/A$1.61 per share1.52
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.56N/AN/A$0.12 per share10.79
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
$15.77M0.00N/AN/A$37.68 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$220.66M-$0.88N/AN/AN/AN/A-52.82%-29.67%8/14/2025 (Estimated)
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.54N/AN/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.55N/AN/A-129.05%-972.55%-77.33%8/15/2025 (Estimated)
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%N/A

Latest CASI, EIGR, AUTL, and CABA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.2329N/AN/AN/A$12.92 millionN/A
8/14/2025Q2 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.71N/AN/AN/AN/AN/A
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
5/16/2025Q1 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.61-$0.69-$0.08-$0.69$7.39 million$6.24 million
5/8/2025Q1 2025
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
N/A
9.24
9.02
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.81
0.68
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
N/A
3.31
3.24

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
72.83%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
62.46%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
25.70%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
11.25%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
4.22%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics PLC Sponsored ADR stock logo
AUTL
Autolus Therapeutics
330266.14 million197.74 millionOptionable
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Eiger BioPharmaceuticals, Inc. stock logo
EIGR
Eiger BioPharmaceuticals
561.48 million1.42 millionOptionable

Recent News About These Companies

Two die in Eiger avalanche
Eiger hosts Gelato Masterclass in Sri Lanka
Remembering John Harlin, Eiger Legend
Eiger Trail
Climbing the iconic Eiger mountain in Switzerland
Eiger Biopharmaceuticals Inc (EIGRQ)
Massive Rockfall on the North Face of the Eiger
Eiger BioPharmaceuticals, Inc. (EIGRQ)
72C.SG,0P00015QPW,0 (72C.SG)
Sentynl acquires Eiger’s Zokinvy for progeria treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$2.44 +0.01 (+0.20%)
As of 11:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.70 +0.02 (+0.89%)
As of 11:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$1.30 -0.03 (-1.89%)
As of 10:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Eiger BioPharmaceuticals stock logo

Eiger BioPharmaceuticals NASDAQ:EIGR

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.